Yale Cancer Center Research Prize and Award for Clinical Excellence
We are pleased to announce two annual, competitive awards in the areas of excellence in research and clinical care for Yale Cancer Center members. All members are encouraged to apply, or nominate a colleague for one of the awards. Each award will be announced at the Yale Cancer Center Conclave on Monday, November 23, 2009.
Learn More >>
Yale Cancer Center Grand Rounds
We continue to have excellent attendance at our weekly Grand Rounds. Thank you for making time in your schedule to attend. I look forward to seeing Yale Cancer Center members each Tuesday at noon in Brady Auditorium for the presentations.
Learn More >>
Yale University has launched our annual United Way campaign. Please consider making a gift to support the Greater New Haven community. This is one way that Yale Cancer Center can give back to the community that supports us.
Learn More >>
Daniel DiMaio, MD, PhD, George Miller, MD, and Joan Steitz, PhD
were awarded a renewal of their program project grant from the
National Cancer Institute
in Tumor Virology. The grant, Molecular Basis of Viral and Cellular Transformation, is for $8 million over the next 5 years.
Judith Grasso, RN
has been promoted to the role of
Patient Services Manager
for the Oncology Service Line. In this new role, Judy oversees the Medical Oncology solid and liquid tumor services at the Long Wharf and Yale Physician's Building facilities. Her role will expand with the opening of the Smilow Cancer Hospital at Yale-New Haven.
The V Foundation for Cancer Research
Qin Yan, PhD
a $200,000 grant to study the role of histone demethylase retinoblastoma binding protein 2 in cancer. Dr. Yan's research will determine the impact of histone demethylase RBP2 on oncogenesis and how its activity contributes to the malignant transformation of cells.
As the week of October 26th fast approaches, construction is focused on the Lower Level where Radiation Oncology will see and treat patients, as well as the first floor lobby. Radiation Oncology will be the first unit to care for patients at the new Smilow Cancer Hospital at Yale-New Haven. Punchlist items are being addressed by the various subcontractors, furniture is starting to be delivered, and coral is being placed into the Lower Level aquarium.
New Clinical Trial Available
HIC Number 0904005078
Principal Investigator: Jonathan Knisely, MD
A Phase III Double-Blind, Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma
Learn More >>
Shared Resource Highlight
Proteomics Shared Resource (PSR)
The Yale Cancer Center Proteomics Shared Resource (PSR) brings state-of-the-art technologies to cancer research. These technologies include a wide range of mass spectrometry, protein identification, and protein profiling technologies, along with biophysical technologies. The latter technologies can be used to quantitatively study protein:protein and protein:ligand interactions which complement and greatly extend the range of available proteomic analyses.
Provide exact/accurate molecular weight information on peptides, proteins, small molecules, oligonucleotides, and other biomolecules that may extend past 100,000 daltons through both mass spectrometry and in solution methods
Quantitatively profile relative protein expression in multiple complex proteomes
Identify and locate protein post-translational modifications
Detect and characterize synthetic intermediates (<5 ppm error on <1,000 dalton compounds)
Identify proteins via MS/MS analysis of in gel tryptic digests
Quantitatively (affinity and kinetics) analyze protein:protein and protein:ligand interactions
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.